Suramin, an Anticancer and Angiosuppressive Agent, Inhibits Endothelial Cell Binding of Basic Fibroblast Growth Factor, Migration, Proliferation, and Induction of Urokinase-Type Plasminogen Activator

Cancer Research

Volumn 54, Issue 10, 1994, Pages 2654-2660

  Takano, Shingo ^a   Gately, Stephen ^a   Neville, Mary E ^b   Herblin, William F ^b   Gross, Janet L ^b   Engelhard, Herbert ^a   Perricone, Michael ^b   Eidsvoog, Kristi ^b   Brem, Steven ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; DNA; HEPARIN; PHORBOL 13 ACETATE 12 MYRISTATE; SURAMIN; UROKINASE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTICLE; BINDING AFFINITY; CAPILLARY ENDOTHELIUM; CATTLE; CELL CYCLE; CELL KINETICS; CELL MIGRATION; CELL PROLIFERATION; CHICKEN; CONTROLLED STUDY; CORNEA; DOSE RESPONSE; EMBRYO; ENDOTHELIUM CELL; FETUS; FLOW CYTOMETRY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PULMONARY ARTERY; RAT; TUMOR GROWTH;

ANIMALS; CELL DIVISION; CELL MOVEMENT; CHICK EMBRYO; CORNEA; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIUM, VASCULAR; ENZYME INDUCTION; FIBROBLAST GROWTH FACTOR 2; MALE; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, WISTAR; SURAMIN; URINARY PLASMINOGEN ACTIVATOR;

EID: 0028318791     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Stein, C. A., La Rocca, R. V., Thomas, R., McAtee, N., and Myers, C. E., Suramin: an anticancer drug with unique mechanism of action. J. Clin. Oncol. 7: 499-508, 1989.
2. Stein, C. A. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res. 53: 2239-2248, 1993.
3. Myers, C., Cooper, M., Stein, C., LaRocca, R., Walther, M. M., Weiss, G., Choyke, P., Dawson, N., Steinberg, S., Uhrich, M. M., Cassidy, J., Kohler, D. R., Trepel, J. and Linehan, D. R., Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 10: 881-889, 1992.
4. Reed, E., Cooper, M. R., LaRocca, R. V., Bostick-Bruton, F. and Myers, C. E., Suramin in advanced platinum-resistant ovarian cancer. Eur. J. Cancer, 28A: 864866, 1992.
5. LaRocca, R. V., Stein, C. A., Danesi, R., Cooper, M. R., Uhrich, M. and Myers, C. E., A pilot study of suramin in the treatment of metastatic renal carcinoma. Cancer (Phila.), 67: 1509-1513, 1991.
6. Eisenberger, M. A., Reyno, L. M., Jodrell, D. I., Sinibaldi, V. J., Tkaczuk, K. H., Sridhara, R., Zuhowski, E. G., Lowitt, M. H., Jacobs, S. C., and Egorin, M. J., Suramin, an active drug for prostate cancer: interium observations in a phase I trial. J. Nad. Cancer Inst. 85: 611-621, 1993.
7. Motzer, R. J., Nanus, D. M., O'Moore, P., Scher, H. I., Bajorin, D. F., Reuter, V., Tong, W. P., Iversen, J., Louison, C., Albino, A. P., and Bosl, G. J., Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res. 52: 5775-5779, 1992.
8. Coffey, R. J., Jr. Leof, E. B., Shipley, G. D., and Moses, H. L., Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J. Cell. Physiol. 132: 143-148, 1987.
9. Bojanowski, K., Lelievre, S., Markovits, J., Couprie, J., Jacquemin-Sablon, A. and Larsen, A. K., Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc. Natl. Acad. Sci. USA, 89: 3025-3029, 1992.
10. Ono, K., Nakane, H., and Fukushima, M. Differential inhibition of various deoxyribonucleic and ribonucleic acid polymerases by suramin. Eur. J. Biochem. 172: 349-353, 1988.
11. Spigelman, Z., Dowers, A., Kennedy, S., DiSorbo, D., O'Brien, M., Barr, R., and McCaffrey, R. Antiproliferative effects of suramin on lymphoid cells. Cancer Res. 47: 4694-4698, 1987.
12. Zabrenetzky, V. S., Kohn, E. C., and Roberts, D. D., Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide. Cancer Res. 50: 5937-5942, 1990.
13. Brem, S. S., Zagzag, D., Tsanaclis, A. M. C., Gately, S., Elkouby, M. P., and Brien, S. E., Inhibition of angiogenesis and tumor growth in the brain: suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am. J. Pathol. 137: 1121-1142, 1990.
14. Folkman, J. and Klagsbrun, M. Angiogenic factors. Science (Washington DC), 235: 442-447, 1987.
15. Folkman, J. What is the evidence that tumors are angiogenesis-dependent? J. Natl. Cancer Inst. 82: 4-6, 1990.
16. Fan, T. P. D., and Brem, S. Angiosuppression. In: M. J. Waring, and B. Ponder (eds.), The Search for New Anticancer Drugs, Vol. 3, pp. 185-229. Dordrecht, The Netherlands: Kluwer Publishers, 1992.
17. Brem, S. Development of therapeutic angiosuppression: problems and progress. In: M., Maragoudakis, P., Gullino, and P. I. Lelkes (eds.), Angiogenesis in Health and Disease, pp. 295-302. New York: Plenum Publishing, 1992.
18. Wilks, J. W., Scott, P. S., Vrba, L. K., and Cocuzza, J. M., Inhibition of angiogenesis with combination treatment of angiostatic steroids and suramin. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 60: 73-77, 1991.
19. Gagliardi, A., Hadd, H., and Collins, D. C., Inhibition of angiogenesis by suramin. Cancer Res. 52: 5073-5075, 1992.
20. Pesenti, E., Sola, F., Mongelli, N., Grandi, M., and Spreafico, F. Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. Br. J. Cancer. 66: 367-372, 1992.
21. Folkman, J. and Shing, Y. Angiogenesis. J. Biol. Chem. 267: 10931-10934, 1992.
22. Crum, R., Szabo, S., and Folkman, J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science (Washington DC), 230: 1375-1378, 1985.
23. Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Einer, V. M., Einer, S. G., and Strieter, R. M., Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science (Washington DC), 258: 1798-1801, 1992.
24. Tamargo, R. J., Leong, K. L., and Brem, H. Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate. J. Neuro-Oncol. 9; 131-138, 1990.
25. Gross, J. L., Moscatelli, D. and Rifkin, D. B., Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro. Proc. Natl. Acad. Sci. USA, 80: 2623-2627, 1983.
26. Morrison, R. S., Gross, J. L., Herblin, W. F., Reilly, T. M., LaSala, P. A., Alterman, R. L., Moskal, J. R., Kornblith, P. L., and Dexter, D. L., Basic fibroblast growth factor-like activity and receptors are expressed in a human glioma cell line. Cancer Res. 50: 2524-2529, 1990.
27. Sato, R. and Rifkin, D. B., Autocrine activities of basic fibroblast factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J. Cell Biol. 107: 1199-1205, 1988.
28. Buttke, T. M., McCubrey, J. A., and Owen, T. C., Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J. Immunol. Methods, 157: 233-240, 1993.
29. Shibui, S., Hoshino, T., Vanderlaan, M. and Gray, J. W., Double labeling with iodo-and bromodeoxyuridine for cell kinetics studies. J. Histochem. Cytochem. 37: 1007-1011, 1989.
30. Engelhard, H. H., Krupka, J. L., and Bauer, K. D., Simultaneous quantification of c-myc oncoprotein, total cellular protein, and DNA content using multiparameter flow cytometry. Cytometry, 12: 68-76, 1991.
31. Presta, M., Maier, J. A. M., Rusnati, M., and Ragnotti, G. Basic fibroblast growth factor: production, mitogenic response, and post-receptor signal transduction in cultured normal and transformed fetal bovine aortic endothelial cells. J. Cell. Physiol. 141: 517-526, 1989.
32. Granelli-Piperno, A. and Reich, E. A study of proteases and protease-inhibitor complexes in biological fluids. J. Exp. Med. 148: 223-224, 1978.
33. Scher, H. I., Jodrell, D. I., Iversen, J. M., Curley, T., Tong, W., Egorin, M. J., and Forrest, A. Use of adaptive control with feedback to individualize suramin dosing. Cancer Res. 52: 64-70, 1992.
34. Schweigerer, L., Neufeld, G., Friedman, J., Abraham, J. A., Fiddes, J. C., and Gospodarowicz, D. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature (Lond.), 325: 257-259, 1987.
35. Vaisman, N., Gospodarowicz, D., and Neufeld, G. Characterization of the receptor for vascular endothelial growth factor. J. Biol. Chem. 256: 19461-19466, 1990.
36. Moscatelli, D. Basic fibroblast growth factor (bFGF) dissociates rapidly from heparan sulfates but slowly from receptors. J. Biol. Chem. 267: 25803-25809, 1992.
37. Cardinelli, M., Sartor, O., and Robbins, K. C., Suramin, an experimental chemother-apeutic drug, activates the receptor for epidermal growth factor and promotes the growth of certain malignant cells. J. Clin. Invest. 89: 1242-1247, 1992.
38. Mitchen, J., Rago, R., and Wilding, G. Effects of suramin on the proliferation of primary epithelial cell cultures derived from normal, benign hyperplastic and cancerous human prostates. Prostate, 22: 75-89, 1993.
39. Kim, J. H., Sherwood, E. R., Sutkowski, D. M., Lee, C. and Kozlowski, J. M., Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alphamediated autocrine growth regulation and cell cycle distribution. J. Urol. 146: 171-176, 1991.
40. Kwaan, H. C., The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev. 11: 291-311, 1992.
41. Behrendt, N., Ronne, E., and Dano, K. Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J. Biol. Chem. 268: 5985-5989, 1993.
42. Ellis, V., Behrendt, N., Ronne, E. and Dano, K. Specific inhibition of the urokinase receptor-mediated plasminogen activation system by the anti-tumor drug suramin. Thromb. Haemostasis, 69: 761, 1993.
43. Lopez, R. L., Peters, G. J., Loenen, A. C., Pizao, P. E., Rijswijk, R. E. N., Wagstaff, J., and Pinedo, H. M., The effect of schedule, protein binding and growth factors on the activity of suramin. Int. J. Cancer, 51: 921-926, 1992.
44. Ewing, M. W., Liu, S. C., Gnarra, J. R., Walther, M. M., Meyers, C. E., and Linehan, W. M., Effect of suramin on the mitogenic response of the human prostate carcinoma cell line PC-3. Cancer (Phila.), 71: 1151-1158, 1993.
45. Zetter, B. R., Angiogenesis: state of the art. Chest 93(Suppl. 3): 159S-166S, 1988.
46. Teicher, B. A., Sotomayor, E. A., and Huang, Z. D., Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 52: 6702-6704, 1992.